{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:49Z","timestamp":1782100189825,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"UCB JAPAN"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00552-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:04:02Z","timestamp":1776683042000},"page":"225-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns in Patients with Late-Onset Myasthenia Gravis\u00a0in Japan: An Insurance Claims Database Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"Akiyuki","family":"Uzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-0754","authenticated-orcid":false,"given":"Makoto","family":"Samukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-0663","authenticated-orcid":false,"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-4364","authenticated-orcid":false,"given":"Izumi","family":"Mishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1291-0670","authenticated-orcid":false,"given":"Kentaro","family":"Taki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1224-6717","authenticated-orcid":false,"given":"Hiroshi","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9376-5324","authenticated-orcid":false,"given":"C\u00e9line","family":"Quelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-443X","authenticated-orcid":false,"given":"Katarzyna","family":"Jab\u0142o\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-7908","authenticated-orcid":false,"given":"Renata","family":"Majewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8033-1298","authenticated-orcid":false,"given":"Yohei","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"552_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"552_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235. https:\/\/doi.org\/10.3390\/jcm10112235.","journal-title":"J Clin Med"},{"issue":"1","key":"552_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/jgs.12629","volume":"62","author":"JM Aragon\u00e8s","year":"2014","unstructured":"Aragon\u00e8s JM, Roura-Poch P, Hern\u00e1ndez-Ocampo EM, Alonso F, Pont-Lluelles M, Xandri I, et al. Myasthenia gravis: a disease of the very old. J Am Geriatr Soc. 2014;62(1):196\u20137. https:\/\/doi.org\/10.1111\/jgs.12629.","journal-title":"J Am Geriatr Soc"},{"issue":"1-2","key":"552_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305(1\u20132):97\u2013102. https:\/\/doi.org\/10.1016\/j.jns.2011.03.004.","journal-title":"J Neurol Sci"},{"issue":"8","key":"552_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003;74(8):1105\u20138. https:\/\/doi.org\/10.1136\/jnnp.74.8.1105.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"552_CR6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","volume":"76","author":"Z Pakzad","year":"2011","unstructured":"Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology. 2011;76(17):1526\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e318217e735.","journal-title":"Neurology"},{"issue":"4","key":"552_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000328863","volume":"36","author":"F Pallaver","year":"2011","unstructured":"Pallaver F, Riviera AP, Piffer S, Ricciardi R, Roni R, Orrico D, et al. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011;36(4):282\u20137. https:\/\/doi.org\/10.1159\/000328863.","journal-title":"Neuroepidemiology"},{"issue":"9","key":"552_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274161","volume":"17","author":"H Yoshikawa","year":"2022","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, et al. Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS ONE. 2022;17(9):e0274161. https:\/\/doi.org\/10.1371\/journal.pone.0274161.","journal-title":"PLoS ONE"},{"issue":"1","key":"552_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.35772\/ghm.2019.01011","volume":"1","author":"H Nakatani","year":"2019","unstructured":"Nakatani H. Population aging in Japan: policy transformation, Sustainable Development Goals, Universal Health Coverage, and social determinates of health. Glob Health Med. 2019;1(1):3\u201310. https:\/\/doi.org\/10.35772\/ghm.2019.01011.","journal-title":"Glob Health Med"},{"key":"552_CR10","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.2147\/ndt.s296714","volume":"18","author":"RM Pascuzzi","year":"2022","unstructured":"Pascuzzi RM, Bodkin CL. Myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome: new developments in diagnosis and treatment. Neuropsychiatr Dis Treat. 2022;18:3001\u201322. https:\/\/doi.org\/10.2147\/ndt.s296714.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"552_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cen3.12180","volume":"6","author":"H Murai","year":"2015","unstructured":"Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol. 2015;6:21\u201331. https:\/\/doi.org\/10.1111\/cen3.12180.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"1","key":"552_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14(1):19\u201327. https:\/\/doi.org\/10.1111\/cen3.12739.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"2","key":"552_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166\u201373. https:\/\/doi.org\/10.1002\/mus.23398.","journal-title":"Muscle Nerve"},{"issue":"6","key":"552_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095496","volume":"15","author":"S Konno","year":"2025","unstructured":"Konno S, Uzawa A, Samukawa M, Todaka H, Mishiro I, Taki K, et al. Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study. BMJ Open. 2025;15(6):e095496. https:\/\/doi.org\/10.1136\/bmjopen-2024-095496.","journal-title":"BMJ Open"},{"key":"552_CR15","doi-asserted-by":"publisher","first-page":"1662173","DOI":"10.3389\/fneur.2025.1662173","volume":"16","author":"M Samukawa","year":"2025","unstructured":"Samukawa M, Konno S, Uzawa A, Taki K, Todaka H, Mishiro I, et al. Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan. Front Neurol. 2025;16:1662173. https:\/\/doi.org\/10.3389\/fneur.2025.1662173.","journal-title":"Front Neurol"},{"issue":"4","key":"552_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00198-005-0027-4","volume":"17","author":"ES Siris","year":"2006","unstructured":"Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50\u201399: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int. 2006;17(4):565\u201374. https:\/\/doi.org\/10.1007\/s00198-005-0027-4.","journal-title":"Osteoporos Int"},{"issue":"10169","key":"552_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364\u201376. https:\/\/doi.org\/10.1016\/s0140-6736(18)32112-3.","journal-title":"Lancet"},{"issue":"1","key":"552_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7\u201316. https:\/\/doi.org\/10.1007\/s12020-018-1588-2.","journal-title":"Endocrine"},{"issue":"1","key":"552_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62\u201370. https:\/\/doi.org\/10.1056\/NEJMcp1012926.","journal-title":"N Engl J Med"},{"issue":"5","key":"552_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126579","volume":"10","author":"S Konno","year":"2015","unstructured":"Konno S, Suzuki S, Masuda M, Nagane Y, Tsuda E, Murai H, et al. Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS ONE. 2015;10(5):e0126579. https:\/\/doi.org\/10.1371\/journal.pone.0126579.","journal-title":"PLoS ONE"},{"key":"552_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Masuda M, Uzawa A, Nagane Y, Konno S, Suzuki Y, et al. Japan MG registry: chronological surveys over 10 years. Clin Exp Neuroimmunol. 2023;14:5\u201312. https:\/\/doi.org\/10.1111\/cen3.12731.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"2","key":"552_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37737\/ace.25006","volume":"7","author":"H Yasunaga","year":"2025","unstructured":"Yasunaga H. DeSC database. Ann Clin Epidemiol. 2025;7(2):46\u20139. https:\/\/doi.org\/10.37737\/ace.25006.","journal-title":"Ann Clin Epidemiol"},{"issue":"2","key":"552_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5(2):190\u20138. https:\/\/doi.org\/10.31662\/jmaj.2021-0189.","journal-title":"JMA J"},{"key":"552_CR24","doi-asserted-by":"publisher","DOI":"10.1265\/ehpm.22-00269","volume":"28","author":"K Ikeda","year":"2023","unstructured":"Ikeda K, Yoshida S, Okazaki Y, Miyamori D, Kashima S, Ishii S, et al. Increased care-need in older long-term care insurance users after the 2018 Japan Floods: a retrospective cohort study based on the Japanese long-term care insurance claims. Environ Health Prev Med. 2023;28:31. https:\/\/doi.org\/10.1265\/ehpm.22-00269.","journal-title":"Environ Health Prev Med"},{"issue":"5","key":"552_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"11","key":"552_CR26","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1592\/phco.27.11.1512","volume":"27","author":"K Asare","year":"2007","unstructured":"Asare K. Diagnosis and treatment of adrenal insufficiency in the critically ill patient. Pharmacotherapy. 2007;27(11):1512\u201328. https:\/\/doi.org\/10.1592\/phco.27.11.1512.","journal-title":"Pharmacotherapy"},{"key":"552_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/jcm.s29601","volume":"6","author":"N Nishikawa","year":"2015","unstructured":"Nishikawa N, Nagai M, Tsujii T, Kyaw WT, Tanabe N, Iwaki H, et al. Treatment of Mmasthenia gravis in patients with elderly onset at advanced age. Jpn Clin Med. 2015;6:9\u201313. https:\/\/doi.org\/10.4137\/jcm.s29601.","journal-title":"Jpn Clin Med."},{"issue":"4","key":"552_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/ncn3.12129","volume":"5","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Nakagawa M, Yoshida T, Yazaki M, Sekijima Y, Hashimoto T, et al. Survey of epidemiology, clinical picture and current treatments for elderly-onset (\u2265\u00a065\u00a0years) patients with myasthenia gravis in Nagano Prefecture, Japan. Neurol Clin Neurosci. 2017;5(4):107\u201312. https:\/\/doi.org\/10.1111\/ncn3.12129.","journal-title":"Neurol Clin Neurosci"},{"key":"552_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1673297","volume":"16","author":"M Kasahara-Kiritani","year":"2025","unstructured":"Kasahara-Kiritani M, Saga Y, Watanabe S, Webb T, Herr K, Yu D, et al. Humanistic burden and medical care patterns of real-world patients with myasthenia gravis in Japan. Front Neurol. 2025;16:1673297. https:\/\/doi.org\/10.3389\/fneur.2025.1673297.","journal-title":"Front Neurol"},{"issue":"10","key":"552_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0334041","volume":"20","author":"H Yoshikawa","year":"2025","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, et al. Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018. PLoS ONE. 2025;20(10):e0334041. https:\/\/doi.org\/10.1371\/journal.pone.0334041.","journal-title":"PLoS ONE"},{"key":"552_CR31","doi-asserted-by":"publisher","DOI":"10.1159\/000512973","author":"E Sobieszczuk","year":"2021","unstructured":"Sobieszczuk E, Napi\u00f3rkowski \u0141, Szczudlik P, Kostera-Pruszczyk A. Myasthenia gravis in Poland: national healthcare database epidemiological study. Neuroepidemiology. 2021. https:\/\/doi.org\/10.1159\/000512973.","journal-title":"Neuroepidemiology"},{"issue":"10","key":"552_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13(10):1006\u201310. https:\/\/doi.org\/10.1016\/j.jocn.2005.12.041.","journal-title":"J Clin Neurosci"},{"key":"552_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nmd.2024.07.002","volume":"43","author":"KH Axelsen","year":"2024","unstructured":"Axelsen KH, Kj\u00e6r Andersen R, Andersen LK, Vissing J, Witting N. Ocular versus generalized myasthenia gravis: a continuum associated with acetylcholine receptor antibody titers. Neuromuscul Disord. 2024;43:39\u201343. https:\/\/doi.org\/10.1016\/j.nmd.2024.07.002.","journal-title":"Neuromuscul Disord"},{"key":"552_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2026.109389","volume":"265","author":"A Yasaka","year":"2026","unstructured":"Yasaka A, Watanabe G, Saito M, Tamagake A, Sasaki C, Akao G, et al. Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin. Clin Neurol Neurosurg. 2026;265:109389. https:\/\/doi.org\/10.1016\/j.clineuro.2026.109389.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"552_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","volume":"1413","author":"H Murai","year":"2018","unstructured":"Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M. Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci. 2018;1413(1):35\u201340. https:\/\/doi.org\/10.1111\/nyas.13544.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"552_CR36","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/m22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304. https:\/\/doi.org\/10.7326\/m22-1460.","journal-title":"Ann Intern Med"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00552-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:39Z","timestamp":1782098379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00552-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"1 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroshi Todaka, Izumi Mishiro, Kentaro Taki, and Yohei Ohashi are employees of UCB, Japan. Akiyuki Uzawa has received honoraria from Alexion Pharmaceuticals, UCB, and Argenx. Makoto Samukawa has received honoraria from Alexion Pharmaceuticals, UCB, and Argenx. Shingo Konno has received lecture honoraria from UCB, Argenx, and Alexion Pharmaceuticals. Renata Majewska and Katarzyna Jab\u0142o\u0144ska are employees of Putnam, a consultancy company who received funding from UCB for the implementation of this study. C\u00e9line Quelen was an employee of Putnam, a consultancy company who received funding from UCB for the implementation of this study, when this study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study complied with all relevant international and national legislation on medical research and data privacy. In particular, it complied with the Declaration of Helsinki (Fortaleza Revision, 2013) and with the Japanese Act on the Protection of Personal Information (Act No. 57, 2003 and subsequent revisions). Furthermore, the study (RI2022016) was approved by the Ethics Review Committee for database studies of the Research Institute of Healthcare Data Science, Tokyo, Japan on 20 April, 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable as all patient data was anonymized prior to extraction from the database.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}